TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Calliditas Therapeutics AB
Closing information (x1000 EUR)
| Closing information | 2025/03 | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Turnover |
180,559
|
108,768
|
72,147 |
| Financial expenses |
49,336
|
10,305
|
3,385 |
| Earnings before taxes |
-58,012
|
-41,188
|
-36,791 |
| EBITDA |
-12,130
|
-32,125
|
-36,756 |
| Total assets |
221,598
|
167,560
|
175,496 |
| Current assets |
108,859
|
114,920
|
126,902 |
| Current liabilities |
65,190
|
36,693
|
29,225 |
| Equity capital |
14,928
|
30,174
|
68,857 |
| - share capital |
221
|
215
|
214 |
| Employees (average) |
62
|
181
|
86 |
Financial ratios
| Fiscal year | 2025/03 | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Solvency |
6.7%
|
18.0%
|
39.2% |
| Turnover per employee |
2,912
|
601
|
839 |
| Profit as a percentage of turnover |
-32.1%
|
-37.9%
|
-51.0% |
| Return on assets (ROA) |
-3.9%
|
-18.4%
|
-19.0% |
| Current ratio |
167.0%
|
313.2%
|
434.2% |
| Return on equity (ROE) |
-388.6%
|
-136.5%
|
-53.4% |
| Change turnover | |||
| Change turnover % |
50%
|
250% | |
| Chg. No. of employees | |||
| Chg. No. of employees % |
110%
|
54% |
Total value of public sale
| Fiscal year | 2025/03 | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.